Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC1R | Q01726 | 8/20 | 0.58 |
| ▸ | MC4R | P32245 | 8/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.31 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.30 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1312466 | 0.88 | MC1R (0.55) | MC1RMC4RAPPMAPT | |
| SCHEMBL1310670 | 0.87 | MC1R (0.54) | MC1RMC4RAPPMAPT | |
| SCHEMBL1311899 | 0.86 | MC1R (0.47) | MC1RMC4ROPRM1OPRD1OPRK1 | |
| SCHEMBL16445351 | 0.83 | MC1R (0.73) | MC1RMC4RAPPGAAMAPT | |
| Trifluoroacetic Acid SCHEMBL1311384 | 0.82 | MC1R (0.58) | MC1RMC4RPOLBOPRM1OPRD1 | |
| SCHEMBL1310666 | 0.81 | MC1R (0.47) | MC1RMC4RGAAMAPT | |
| SCHEMBL2149032 | 0.81 | MC1R (0.62) | MC1RMC4RAPPGAAMAPT | |
| SCHEMBL1310043 | 0.80 | MC1R (0.55) | MC1RMC4RAPP | |
| SCHEMBL1310558 | 0.77 | MC1R (0.69) | MC1RMC4R | |
| SCHEMBL1309794 | 0.76 | MC1R (0.44) | MC1RMC4RAPPMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871187-B2 | Oxoazetidine derivatives, process for the preparation thereof and use thereon in human medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-10-28 | — | — | US | disclosed |
| US-20110274638-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREON IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110274638-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREON IN HUMAN MEDICINE AND IN COSMETICS | CYP2D6, CYP51A1, CYP2C19 | MC1R 326/4885MC4R 1479/4885APP 3016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.